Metabasis/Sankyo initiate Ph IIb CS-917 trial
The USA's Metabasis Therapeutics says that Japanese drugmaker Sankyo has initiated a multicenter, double-blind, placebo-controlled Phase IIb trial designed to evaluate the safety and efficacy of the former's CS-917 for the treatment of patients with type 2 diabetes.
CS-917, a first-in-class, orally-active, inhibitor of FBPase, an enzyme that regulates production of glucose in the liver, has shown promise as a treatment for diabetes in preclinical and early clinical studies. Sankyo is Metabasis' strategic partner and licensee for CS-917. It funds and directs the clinical development of the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze